{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:45:32Z","timestamp":1790469932171,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>Pathogenic molecular features gained specific significance in therapeutic decisions in lung carcinoma in the past decade. Initial and follow up genetic testing requres appropriate amounts and quality of tumor derived DNA, but tumor sampling, especially for disease monitoring is generally limited. Further to the peripheral blood (PB), samples from pleural fluid, accumulating in diverse lung processes might serve as an alternative source for cell-free DNA (cfDNA) for genetic profiling. In our study, cfDNA isolated from the pleural effusion and from the PB, and genomic DNA (gDNA) obtained from tissue\/cellular samples were analyzed and compared from altogether 65 patients with pulmonary disease, including 36 lung adenocarcinomas. The quantity of effusion cfDNA yield appeared to be significantly higher compared to that from simultaneously collected PB plasma (23.2 vs. 4.8 ng\/\u03bcl, <jats:italic>p<\/jats:italic> &amp;lt; 0.05). Gene mutations could be safely demonstrated from the effusion cfDNA fraction obtained from adenocarcinoma patients, 3\/36 <jats:italic>EGFR<\/jats:italic>, 9\/36 <jats:italic>KRAS<\/jats:italic> and 1\/36 <jats:italic>BRAF<\/jats:italic> gene variants were detected. In this series, 9\/13 samples showed an effusion+\/plasma-mutational status, while only 1\/13 samples presented with the opposite findings (effusion-\/plasma+). gDNA analysis from sediment cell blocks from the identical effusion sample was surprisingly ineffective for lung adenocarcinoma profiling due to the low DNA yield. In conclusion, the cell free supernatant of pleural effusions appears to concentrate cancer derived cfDNA and seems to be particularly suitable for serial genotyping of pulmonary adenocarcinoma.<\/jats:p>","DOI":"10.3389\/pore.2021.613071","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T04:12:42Z","timestamp":1617077562000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Cell-free DNA From Pleural Effusion Samples: Is It Right for Molecular Testing in Lung Adenocarcinoma?"],"prefix":"10.3389","volume":"27","author":[{"given":"Attila","family":"Mok\u00e1nszki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese Sarolta","family":"B\u00e1don","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik\u00f3","family":"M\u00f3nus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"M\u00e9hes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1755-8794-2-8","article-title":"High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays","volume":"2","author":"Wang","year":"2009","journal-title":"BMC Med Genomics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"61ra91","DOI":"10.1126\/scitranslmed.3001720","article-title":"Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus","volume":"2","author":"Lo","year":"2010","journal-title":"Sci Translational Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1200\/edbk_199765","article-title":"Liquid biopsy to identify actionable genomic alterations","volume":"38","author":"Ou","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non-small cell lung cancer (nsclc): a statement paper from the iaslc","volume":"13","author":"Rolfo","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jbiotec.2019.04.002","article-title":"Liquid biopsy for predictive mutational profiling of solid cancer: the pathologist's perspective","volume":"297","author":"M\u00e9hes","year":"2019","journal-title":"J Biotechnol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3389\/fonc.2019.00775","article-title":"Liquid biopsy in oligometastatic prostate cancer-A biologist\u2019s point of view","volume":"9","author":"Stelcer","year":"2019","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2217\/fon.11.45","article-title":"Diagnostic molecular biomarkers for malignant pleural effusions","volume":"7","author":"Sriram","year":"2011","journal-title":"Future Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/pgmj.2005.035352","article-title":"Pleural effusion","volume":"81","author":"Medford","year":"2005","journal-title":"Postgrad Med J"},{"key":"B11","first-page":"19","article-title":"The diagnostic yield of pleural fluid cytology in malignant pleural effusions","volume":"41","author":"Ong","year":"2000","journal-title":"Singapore Med J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1378\/chest.111.1.106","article-title":"The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma","volume":"111","author":"Renshaw","year":"1997","journal-title":"Chest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1158\/1535-7163.mct-16-0436","article-title":"Cell-free DNA from ascites and pleural effusions: molecular insights into genomic aberrations and disease biology","volume":"16","author":"Husain","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.csbj.2016.05.004","article-title":"Circulating biomarkers to monitor cancer progression and treatment","volume":"14","author":"Rapisuwon","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdy009","article-title":"Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy","volume":"29","author":"Li","year":"2018","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/15384047.2018.1504720","article-title":"Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient","volume":"20","author":"Zhou","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"ii4","DOI":"10.1136\/thx.2010.136978","article-title":"Investigation of a unilateral pleural effusion in adults: British thoracic society pleural disease guideline 2010","volume":"65","author":"Hooper","year":"2010","journal-title":"Thorax"},{"key":"B18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/s0002-9610(99)80257-8","article-title":"Diagnosis and management of malignant pleural effusions","volume":"170","author":"Fenton","year":"1995","journal-title":"Am J Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1515\/cclm-2016-0851","article-title":"Assessment of real-time PCR method for detection of EGFR mutation using both supernatant and cell pellet of malignant pleural effusion samples from non-small-cell lung cancer patients","volume":"55","author":"Shin","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1513\/AnnalsATS.201609-709OC","article-title":"Molecular profiling of malignant pleural effusion in metastatic non-small-cell lung carcinoma. The effect of preanalytical FactorsThe effect of preanalytical factors","volume":"14","author":"Carter","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.21037\/jtd.2018.04.125","article-title":"Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens","volume":"10","author":"Liu","year":"2018","journal-title":"J Thorac Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jmoldx.2017.10.007","article-title":"Comprehensive genomic profiling of malignant effusions in patients with metastatic lung adenocarcinoma","volume":"20","author":"Yang","year":"2018","journal-title":"J Mol Diagn"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1016\/j.cca.2011.07.027","article-title":"Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations","volume":"412","author":"Pinzani","year":"2011","journal-title":"Clinica Chim Acta"},{"key":"B24","first-page":"3966","article-title":"Increased plasma DNA integrity in cancer patients","volume":"63","author":"Wang","year":"2003","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbamcr.2015.10.022","article-title":"Characterization of the cell-free DNA released by cultured cancer cells","volume":"1863","author":"Bronkhorst","year":"2016","journal-title":"Biochim Biophys Acta (Bba) - Mol Cel Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/jto.0b013e3182307f98","article-title":"Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin\/paclitaxel in non-small cell lung cancer","volume":"7","author":"Goto","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1158\/1078-0432.ccr-08-2622","article-title":"Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients","volume":"15","author":"Yung","year":"2009","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1111\/1759-7714.13201","article-title":"Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma","volume":"10","author":"Zhang","year":"2019","journal-title":"Thorac Cancer"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2021.613071\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T14:42:57Z","timestamp":1626187377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2021.613071\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":28,"alternative-id":["10.3389\/pore.2021.613071"],"URL":"https:\/\/doi.org\/10.3389\/pore.2021.613071","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"article-number":"613071"}}